With $340M crossover fund, Sofinnova Partners pivots to late-stage biotech investments while maintaining European focus
After years backing early-stage life science companies, Sofinnova Partners now has a crossover fund flush with $340.5 million (€275 million) to invest in both public …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
